1
Pablo Umaña, Joël Jean Mairet, James E Bailey: Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity. Glycart Biotechnology, Sterne Kessler Goldstein & Fox p l l c, August 5, 2003: US06602684 (224 worldwide citation)

The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that i ...


2
Pablo Umaña, Joël Jean Mairet, M Sean Bailey legal representative: Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity. GlycArt Biotechnology, Sterne Kessler Goldstein & Fox PLLC, April 14, 2009: US07517670 (35 worldwide citation)

The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that i ...


3
Pablo Umaña, Joël Jean Mairet, James E Bailey: Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity. Roche GlycArt, Sterne Kessler Goldstein & Fox P L L C, Timothy J Shea Jr, January 7, 2014: US08623644 (14 worldwide citation)

The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that i ...


4
Pablo Umaña, Joël Jean Mairet, James E Bailey: Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity. Roche GlycArt, Sterne Kessler Goldstein & Fox P L L C, Timothy J Shea Jr, January 14, 2014: US08629248 (13 worldwide citation)

The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that i ...


5
Pablo Umaña, Joël Jean Mairet, James E Bailey, M Sean Bailey legal representative: Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity. Roche GlycArt, Sterne Kessler Goldstein & Fox P L L C, September 20, 2011: US08021856 (13 worldwide citation)

The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to glycosylation engineering to generate proteins with improved therapeutic properties, including antibodies with increased antibody-dependent cellular cytotoxicity.


6
Pablo Umaña, Joël Jean Mairet, James E Bailey: Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity. Roche GlyeArt, Sterne Kessler Goldstein & Fox P L L C, Timothy J Shea Jr, September 22, 2015: US09139654 (2 worldwide citation)

The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that i ...


7
Pablo Umaña, Joël Jean Mairet, James E Bailey: Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity. Roche GlycArt, Sterne Kessler Goldstein & Fox PLLC, April 7, 2015: US08999324 (2 worldwide citation)

The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to glycosylation engineering to generate proteins with improved therapeutic properties, including antibodies with increased antibody-dependent cellular cytotoxicity.


8
Pablo Umaña, Joël Jean Mairet, James E Bailey: Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity. Roche GlycArt, Sterne Kessler Goldstein & Fox P L L C, June 30, 2015: US09068005 (2 worldwide citation)

The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that i ...


9
Pablo Umaña, Joël Jean Mairet, James E Bailey: Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity. Roche Glycart, Sterne Kessler Goldstein & Fox P L L C, April 26, 2016: US09321843 (1 worldwide citation)

The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to glycosylation engineering to generate proteins with improved therapeutic properties, including antibodies with increased antibody-dependent cellular cytotoxicity.


10
Pablo Umaña, Joël Jean Mairet, James E Bailey: Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity. ROCHE GLYCART, Sterne Kessler Goldstein and Fox P L L C, April 25, 2017: US09631023

The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to glycosylation engineering to generate proteins with improved therapeutic properties, including antibodies with increased antibody-dependent cellular cytotoxicity.